CG
BIO icon

Colony Group’s Bio-Rad Laboratories Class A BIO Stock Holding History

Colony Group’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-1,380
Closed -$661K – 765
2023
Q1 		$661K Sell
1,380
-7
-0.5% -$3.28K 0.01% 515
2022
Q4 		$583K Sell
1,387
-447
-24% -$180K 0.01% 597
2022
Q3 		$765K Sell
1,834
-335
-15% -$167K 0.01% 493
2022
Q2 		$1.07M Sell
2,169
-20
-0.9% -$10.4K 0.02% 435
2022
Q1 		$1.23M Buy
2,189
+1,298
+146% +$782K 0.02% 438
2021
Q4 		$673K Buy
891
+18
+2% +$13.5K 0.01% 529
2021
Q3 		$651K Buy
873
+35
+4% +$26.2K 0.01% 518
2021
Q2 		$540K Sell
838
-64
-7% -$39K 0.01% 508
2021
Q1 		$515K Buy
902
+453
+101% +$268K 0.01% 518
2020
Q4 		$262K Buy
+449
New +$256K 0.01% 644
2014
Q2 		– Sell
-20
Closed -$3K – 755
2014
Q1 		$3K Buy
+20
New +$2.56K ﹤0.01% 725

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
Brown Advisory
Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Westfield Capital Management
Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Colony Group's BIO Position: Q2 2023 in Review

Colony Group sold out of Bio-Rad Laboratories Class A (BIO) in Q2 2023, closing a stake of 1,380 shares — an estimated $661K sold.

Colony Group first reported a position in BIO in Q1 2014 and held it in 11 quarters. The position peaked at $1.23M in Q1 2022. 469 funds tracked by Wall St. Rank hold BIO as of Q2 2023.

  • Colony Group reported no remaining Bio-Rad Laboratories Class A position as of Q2 2023 after selling out during the quarter.
  • Colony Group sold 1,380 Bio-Rad Laboratories Class A shares in Q2 2023, an estimated $661K.
  • Colony Group first reported a position in Bio-Rad Laboratories Class A in Q1 2014 and held it in 11 quarters.
  • Colony Group's Bio-Rad Laboratories Class A position peaked at $1.23M in Q1 2022.
  • 469 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q2 2023.

Based on Colony Group's 13F filing for Q2 2023, filed 15 Aug 2023.